<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310128</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-044</org_study_id>
    <secondary_id>CDR0000467797</secondary_id>
    <nct_id>NCT00310128</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase II Study of Induction Therapy Comprising Etoposide, Methylprednisolone, Cytarabine, and Cisplatin (ESHAP) Followed by Consolidation Therapy Comprising Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Malignancy Consortium</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as etoposide, methylprednisolone, cytarabine, and&#xD;
      cisplatin, work in different ways to stop the growth of cancer cells, either by killing the&#xD;
      cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab and yttrium&#xD;
      Y 90 ibritumomab tiuxetan, can block cancer growth in different ways. Some block the ability&#xD;
      of cancer cells to grow and spread. Others find cancer cells and help kill them or carry&#xD;
      cancer-killing substances to them without harming normal cells. Giving more than one drug&#xD;
      (combination chemotherapy) together with rituximab and yttrium Y 90 ibritumomab tiuxetan may&#xD;
      kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together&#xD;
      with rituximab and yttrium Y 90 ibritumomab tiuxetan works in treating patients with relapsed&#xD;
      or refractory AIDS-related non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the overall survival rate at one year in patients with relapsed or refractory&#xD;
           AIDS-related non-Hodgkin's lymphoma treated with consolidation therapy comprising&#xD;
           rituximab and yttrium Y 90 ibritumomab tiuxetan (radioimmunotherapy) given after&#xD;
           induction therapy comprising etoposide, methylprednisolone, cytarabine, and cisplatin&#xD;
           (ESHAP).&#xD;
&#xD;
        -  Describe the toxicity profile of radioimmunotherapy as consolidation therapy, including&#xD;
           changes in immunologic and virologic parameters over time, in these patients.&#xD;
&#xD;
        -  Determine the overall disease-free survival of patients receiving ESHAP as induction&#xD;
           therapy followed by radioimmunotherapy as consolidation therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the effect of ESHAP as induction therapy and radioimmunotherapy as&#xD;
           consolidation therapy on HIV-1 viral load, CD4 and CD8 cells, and quantitative&#xD;
           immunoglobulin levels in patients on concurrent highly active antiretroviral therapy&#xD;
           (HAART).&#xD;
&#xD;
        -  Determine the objective response rates (complete and partial response) in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of ESHAP as induction therapy in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Induction therapy: Patients receive ESHAP chemotherapy comprising etoposide IV over 2&#xD;
           hours on days 1-4, methylprednisolone IV over 15-30 minutes on days 1-5, cisplatin IV&#xD;
           continuously over 96 hours on days 1-4, and cytarabine IV over 2 hours on day 5.&#xD;
           Treatment repeats every 21-28 days for up to 4 courses in the absence of disease&#xD;
           progression or unacceptable toxicity. Approximately 21-52 days after completion of ESHAP&#xD;
           chemotherapy, patients proceed to consolidation therapy.&#xD;
&#xD;
        -  Consolidation therapy: Patients receive radioimmunotherapy comprising rituximab IV over&#xD;
           3-4 hours followed by indium In 111 ibritumomab tiuxetan (for radioimaging) IV over 10&#xD;
           minutes on day 1. Patients then undergo imaging on days 1 and 2. If biodistribution is&#xD;
           acceptable, patients receive rituximab IV over 3-4 hours followed by yttrium Y 90&#xD;
           ibritumomab tiuxetan IV over 10 minutes on day 8.&#xD;
&#xD;
      After completing study treatment, patients are followed every 2 months for 1 year and then&#xD;
      every 6 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Drug supply unavailable&#xD;
  </why_stopped>
  <start_date>February 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>AIDS-related Lymphoma</condition>
  <condition>Adult Non-Hodgkin's Lymphoma</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>yttrium Y 90 ibritumomab tiuxetan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antibody therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>monoclonal antibody therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radioimmunotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radioisotope therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically documented B-cell non-Hodgkin's lymphoma, including&#xD;
             any of the following histologic types:&#xD;
&#xD;
          -  Follicular large B-cell lymphoma (follicular, grade 3)&#xD;
&#xD;
          -  Follicular mixed cell lymphoma (follicular, grade 2)&#xD;
&#xD;
          -  Diffuse mixed cell lymphoma&#xD;
&#xD;
          -  Diffuse large B-cell lymphoma&#xD;
&#xD;
          -  Immunoblastic lymphoma&#xD;
&#xD;
          -  Burkitt or Burkitt-like lymphoma&#xD;
&#xD;
          -  Anaplastic large cell lymphoma&#xD;
&#xD;
          -  Primary effusion lymphoma&#xD;
&#xD;
          -  All stages eligible&#xD;
&#xD;
          -  Seropositive for HIV by any approved test or positive HIV-1 RNA in plasma at anytime&#xD;
             in the past&#xD;
&#xD;
          -  Prior documentation of HIV seropositivity allowed&#xD;
&#xD;
          -  Received 1 prior anthracycline-based regimen of curative intent&#xD;
&#xD;
          -  No more than 1 prior regimen&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Evaluable disease defined as not having bidimensional measurements (i.e., gastric or&#xD;
             marrow involvement) but can be followed for response by other diagnostic tests, such&#xD;
             as gallium scan, positron emission tomography (PET) imaging and/or bone marrow biopsy&#xD;
&#xD;
          -  No primary CNS lymphoma&#xD;
&#xD;
          -  Lymphomatous meningitis or brain metastasis eligible provided other measurable&#xD;
             systemic lymphomatous disease is also present&#xD;
&#xD;
          -  Less than 25% bone marrow involvement with lymphoma&#xD;
&#xD;
          -  Concurrent effective highly active anti-retroviral therapy (HAART) required at study&#xD;
             entry&#xD;
&#xD;
          -  HIV viral load &lt; 100,000 copies/mL if HAART was not used previously&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 50-100%&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL (unless elevated due to lymphomatous involvement of the liver or&#xD;
             biliary tract OR due to other HIV medications [e.g., indinavir or atazanavir])&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL (&lt; 2.6 mg/dL if due to use of tenofovir or truvada) OR&#xD;
             creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Granulocyte count &gt; 1,000/mm^3 (unless abnormal due to lymphomatous involvement of the&#xD;
             bone marrow)&#xD;
&#xD;
          -  Platelet count &gt; 75,000/mm^3 (unless abnormal due to lymphomatous involvement of the&#xD;
             bone marrow or HIV-related thrombocytopenia)&#xD;
&#xD;
          -  No acute intercurrent infection that may interfere with study participation&#xD;
&#xD;
          -  Mycobacterium avium allowed&#xD;
&#xD;
          -  No second active tumor except nonmelanomatous skin cancer, carcinoma in situ of the&#xD;
             cervix, or Kaposi's sarcoma not requiring systemic chemotherapy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No serious, ongoing nonmalignant disease or infection that would compromise study&#xD;
             objectives&#xD;
&#xD;
          -  No antimurine antibody (HAMA) reactivity&#xD;
&#xD;
          -  No history of any cutaneous or mucocutaneous reaction from prior rituximab&#xD;
             administration&#xD;
&#xD;
          -  No history of cutaneous or mucocutaneous reactions or diseases severe enough to cause&#xD;
             hospitalization or an inability to eat for ≥ 2 days&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Fully recovered from all toxicities associated with prior surgery, radiotherapy,&#xD;
             chemotherapy, or immunotherapy&#xD;
&#xD;
          -  Prior chronic therapy with potentially myelosuppressive agents allowed provided&#xD;
             hematologic criteria are met at study entry&#xD;
&#xD;
          -  No radiotherapy within the past 4 weeks, unless for emergency conditions secondary to&#xD;
             lymphoma (i.e., cord compression)&#xD;
&#xD;
          -  No anticancer therapy within the past 3 weeks (6 weeks for nitrosourea or mitomycin C)&#xD;
&#xD;
          -  No rituximab within 6 weeks before study radioimmunotherapy&#xD;
&#xD;
          -  No investigational agent(s) within the past 4 weeks, unless these are antiretroviral&#xD;
             agents available on a compassionate use basis&#xD;
&#xD;
          -  No prior external beam radiotherapy to &gt; 25% of active bone marrow (involved field or&#xD;
             regional)&#xD;
&#xD;
          -  No major surgery, other than diagnostic surgery, within the past 4 weeks&#xD;
&#xD;
          -  No prior myeloablative therapies with autologous bone marrow transplantation,&#xD;
             peripheral blood stem cell rescue, or failed stem cell collection&#xD;
&#xD;
          -  No prior radioimmunotherapy&#xD;
&#xD;
          -  No pegfilgrastim within 4 weeks before study radioimmunotherapy&#xD;
&#xD;
          -  No other growth factors within 2 weeks before and after study radioimmunotherapy&#xD;
&#xD;
          -  No other concurrent myelosuppressive antineoplastic agents after receipt of study&#xD;
             radioimmunotherapy until blood counts recover&#xD;
&#xD;
          -  No zidovudine-containing regimens (including lamivudine and trizivir) during and for ≥&#xD;
             2 months after completion of study radioimmunotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra M. Levine, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anil Tulpule, MD</last_name>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>March 29, 2006</study_first_submitted>
  <study_first_submitted_qc>March 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIDS-related diffuse large cell lymphoma</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related small noncleaved cell lymphoma</keyword>
  <keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
  <keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult Burkitt's lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt's lymphoma</keyword>
  <keyword>recurrent adult Burkitt's lymphoma</keyword>
  <keyword>stage I adult Burkitt's lymphoma</keyword>
  <keyword>stage III adult Burkitt's lymphoma</keyword>
  <keyword>stage IV adult Burkitt's lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphoma, AIDS-Related</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

